Drug Dosage & Administration. Patients in stratum 1 received fondaparinux 2.5 mg or placebo once daily in a blinded manner for up to 8 days or until hospital discharge. Stratum 2 patients received ...

We attempted to include only patients whose anti-factor Xa concentrations were obtained from samples collected at steady state and at the appropriate time after a fondaparinux dose. We used a ...

A study has revealed that fondaparinux, a synthetic inhibitor of coagulation factor Xa, is a promising treatment option for patients with acute coronary syndromes. Mehta et al. performed a ...

Recent data have shown that fondaparinux, a selective factor Xa inhibitor, is noninferior to enoxaparin for short-term prevention of adverse cardiovascular outcomes in patients with non-ST-segment ...